A Study of Iron Oligosaccharide in CHF Patients

Status Completed

Clinical Trial Summary

The purpose of this study is to determine the safety profile of iron oligosaccharide in patients with congestive heart failure with a need for parenteral iron.

Clinical Trial Description

Iron dextrans have been marketed for more than 50 years and the compiled preclinical and clinical experience with iron dextrans in general is well established. Pharmacosmos A/S already markets the iron dextran CosmoFer® worldwide, except in the US where the product is named INFeD®. A new iron oligosaccharide has been manufactured by Pharmacosmos A/S and it is a further development of CosmoFer® where ferric hydroxide has been combined with low molecular weight oligosaccharides in a relatively strong complex. This iron carbohydrate complex builds on the well established efficacy and safety profile of existing iron dextran but with a significantly reduced anaphylactic potential.

In order to ensure that iron oligosaccharide will not lead to unexpected adverse events the existing clinical information on iron dextrans in general needs to be supplied with clinical safety data from a limited number of relevant patients exposed to iron oligosaccharide in open label non-comparator studies.

The primary objective of the present study is to obtain safety reassurance with the use of iron oligosaccharide given either as repeated IV boluses or as total dose infusion for the correction of anaemia in patients with congestive heart failure in order to ensure that iron oligosaccharide will not lead to unexpected adverse events in these patients. ;

Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00537186
Study type	Interventional
Source	Pharmacosmos A/S
Contact
Status	Completed
Phase	Phase 3
Start date	June 2007
Completion date	July 2008

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01357850` - A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure	Phase 2
Recruiting	`NCT00532688` - N-Acetylcysteine in Heart Failure With Coexistent Chronic Renal Failure	Phase 2/Phase 3
Terminated	`NCT00383630` - Bone Marrow Cell Transplantation to Improve Heart Function in Individuals With End-Stage Heart Failure	Phase 2
Completed	`NCT00531661` - CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients	N/A
Completed	`NCT00241761` - Epidemiology of Depression and Heart Failure in Aging	N/A
Terminated	`NCT00125437` - Larger Dose of Spironolactone for the Treatment of Patients With Nonischemic Cardiomyopathy	N/A
Completed	`NCT00159614` - Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment	Phase 2
Completed	`NCT00149435` - Cardiovascular Health Study (CHS) Events Follow-up Study
Completed	`NCT00202579` - Efficacy and Safety of Ivabradine in Severe Congestive Heart Failure	Phase 2
Completed	`NCT00094263` - Long-Term Predictors of Morbidity in Older Age	N/A
Terminated	`NCT00357591` - Randomized Trial for Patients With Chronic Heart Failure With Acute Decompensation	N/A
Completed	`NCT00048425` - Evaluation of Intravenous Levosimendan Efficacy in the Short Term Treatment of Decompensated Chronic Heart Failure.	Phase 3
Completed	`NCT00023556` - Genetic Architecture of Heart Disease in Rural Brazil	N/A
Completed	`NCT00530426` - Heart Failure Registry	Phase 4
Terminated	`NCT00190359` - Growth Hormone and Heart Failure	N/A
Completed	`NCT00004562` - Occluded Artery Trial (OAT)	Phase 3
Completed	`NCT00005265` - Natural History of Coronary Heart Disease	N/A
Completed	`NCT02772068` - Hemodynamic Response to Exercise in HFpEF Patients After Upregulation of SERCA2a	Early Phase 1
Completed	`NCT02925546` - A Phase I Study to Assess the Pharmacokinetics of GSK2798745 Tablets	Phase 1
Completed	`NCT01074307` - A Prospective, Open-labeled, Multi-centric Trial in Subjects With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea	Phase 4